AEs
| AE . | All grades, n (%) . | Grade ≥3, n (%) . |
|---|---|---|
| 52 (100) . | 33 (63.5) . | |
| COVID-19 | 21 (40.4) | 6 (11.5) |
| Hematoma | 19 (36.5) | 0 |
| Diarrhea | 12 (23.1) | 1 (1.9) |
| Anemia | 9 (17.3) | 6 (11.5) |
| Constipation | 9 (17.3) | 0 |
| Headache | 9 (17.3) | 0 |
| Fatigue | 8 (15.4) | 0 |
| Edema peripheral | 8 (15.4) | 0 |
| Contusion | 7 (13.5) | 0 |
| Thrombocytopenia | 6 (11.5) | 1 (1.9) |
| Vertigo | 6 (11.5) | 0 |
| Dehydration | 6 (11.5) | 1 (1.9) |
| Rash | 6 (11.5) | 2 (3.8) |
| Nausea | 6 (11.5) | 0 |
| Cardiac failure | 4 (7.7) | 3 (5.8) |
| Palpitations | 4 (7.7) | 0 |
| Hypertension | 1 (1.9) | 0 |
| Hypertensive crisis | 1 (1.9) | 0 |
| AE . | All grades, n (%) . | Grade ≥3, n (%) . |
|---|---|---|
| 52 (100) . | 33 (63.5) . | |
| COVID-19 | 21 (40.4) | 6 (11.5) |
| Hematoma | 19 (36.5) | 0 |
| Diarrhea | 12 (23.1) | 1 (1.9) |
| Anemia | 9 (17.3) | 6 (11.5) |
| Constipation | 9 (17.3) | 0 |
| Headache | 9 (17.3) | 0 |
| Fatigue | 8 (15.4) | 0 |
| Edema peripheral | 8 (15.4) | 0 |
| Contusion | 7 (13.5) | 0 |
| Thrombocytopenia | 6 (11.5) | 1 (1.9) |
| Vertigo | 6 (11.5) | 0 |
| Dehydration | 6 (11.5) | 1 (1.9) |
| Rash | 6 (11.5) | 2 (3.8) |
| Nausea | 6 (11.5) | 0 |
| Cardiac failure | 4 (7.7) | 3 (5.8) |
| Palpitations | 4 (7.7) | 0 |
| Hypertension | 1 (1.9) | 0 |
| Hypertensive crisis | 1 (1.9) | 0 |
Data are presented at the patient level for the safety population (n = 52). Depicted are AEs with an occurrence of ≥10% of all patients, and cardiac AEs with an occurrence of ≥5%.